Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the needed area.</li><li> The company's stock has performed exceptionally well in Canada and is expanding its presence in the US.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company's stock has performed exceptionally well in Canada and is expanding its presence in the US.

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the needed area.</li><li> The company is also expanding its potential treatments with ExoPTEN and announced preclinical results that showed promise in repairing optic nerve damage.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company is also expanding its potential treatments with ExoPTEN and announced preclinical results that showed promise in repairing optic nerve damage.

NRXBF: New Test Results Opens Potential New Market

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the needed area.</li><li> The company released its 3Q earnings results that highlighted the progress the company has made and also showed management's commitment to controlling expenses.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company released its 3Q earnings results that highlighted the progress the company has made and also showed management's commitment to controlling expenses.

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the needed area.</li><li> The company recently announced that its ExoPTEN spinal cord therapy has been granted Orphan Medicinal Product Designation by the European Medicines Agency.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company recently announced that its ExoPTEN spinal cord therapy has been granted Orphan Medicinal Product Designation by the European Medicines Agency.

NRXBF:  Signature Treatment Gets Important Designation

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the needed area.</li><li> The company has conducted preclinical testing that has shown dramatic results and has been awarded an important FDA designation.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company has conducted preclinical testing that has shown dramatic results and has been awarded an important FDA designation.

NRXBF:  Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries

Israel

NurExone Biologic Inc. operates as a biotech company. The Company develops novel, biologic, and minimal-invasive treatment for spinal cord injury and traumatic brain injury. NurExone Biologic serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nurexone Biologic (NRXBF US)

NRXBF: US Investors Should Pay Attention

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

NRXBF: New Test Results Opens Potential New Market

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

NRXBF: Company Remains on Track

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

NRXBF: Signature Treatment Gets Important Designation

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

NRXBF: Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)